Analysts on Wall Street project that Moderna (MRNA) will announce quarterly loss of $2.65 per share in its forthcoming report, representing a decline of 581.8% year over year. Revenues are projected ...

The bill would implement a moratorium for a decade. “I am not against vaccination in any way,” the freshman lawmaker said.

Media OutReach Newswire – 5 February 2025 – AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced today that its independently developed ...

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for ...

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

Moderna (NASDAQ:MRNA) earlier projected revenues for fiscal year 2025 to settle between $1.5 billion and $2.5 billion. While recognizing that products in Moderna’s pipeline could contribute to ...

New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), ...

The platform’s scalability, rapid production and relatively straightforward manufacturing process mean that mRNA therapeutics are a powerful alternative to traditional small molecule drugs and DNA ...

In mRNA manufacturing, it helps ensure the purity and quality of the final mRNA product. Dyadic’s C1 produced DNAse1 holds a certificate of analysis and the product is ready for non-GMP ...

The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on regulatory guidance for ...

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.